BACKGROUND: We explored use of a canine model of heart failure (HF) for pharmacogenomic discovery, specifically analyzing response to beta blockers (BB). METHODS: Dogs with HF that received BB (n=39) underwent genome-wide genotyping to test the association with changes in left ventricular (LV) volume and ejection fraction after treatment. Resulting candidate genes underwent RNA quantification in cardiac tissue from normal (n=5), placebo-HF (n=5), and BB-HF (n=7) dogs. RESULTS: Three markers met whole-genome significance for association with improved LV end-systolic volume after BB therapy (each p<5 x 10(-7)). RNA quantification of three candidate genes near these markers -- GUCA1B, RRAGD, and MRPS10 -- revealed that gene expression levels in BB-HF dogs were between that of placebo-HF dogs and normal dogs. CONCLUSION: Genome-wide pharmacogenomic screening in a canine model of HF suggests 3 novel BB response candidate loci. This approach is adaptable to discovering mechanisms of action for other drug therapies, and may be a useful strategy for identifying candidate genes for drug response in the pre-clinical setting.
BACKGROUND: We explored use of a canine model of heart failure (HF) for pharmacogenomic discovery, specifically analyzing response to beta blockers (BB). METHODS:Dogs with HF that received BB (n=39) underwent genome-wide genotyping to test the association with changes in left ventricular (LV) volume and ejection fraction after treatment. Resulting candidate genes underwent RNA quantification in cardiac tissue from normal (n=5), placebo-HF (n=5), and BB-HF (n=7) dogs. RESULTS: Three markers met whole-genome significance for association with improved LV end-systolic volume after BB therapy (each p<5 x 10(-7)). RNA quantification of three candidate genes near these markers -- GUCA1B, RRAGD, and MRPS10 -- revealed that gene expression levels in BB-HF dogs were between that of placebo-HF dogs and normal dogs. CONCLUSION: Genome-wide pharmacogenomic screening in a canine model of HF suggests 3 novel BB response candidate loci. This approach is adaptable to discovering mechanisms of action for other drug therapies, and may be a useful strategy for identifying candidate genes for drug response in the pre-clinical setting.
Authors: David E Lanfear; Philip G Jones; Sharon Marsh; Sharon Cresci; Howard L McLeod; John A Spertus Journal: JAMA Date: 2005-09-28 Impact factor: 56.272
Authors: Steven G Terra; Karen K Hamilton; Daniel F Pauly; Craig R Lee; J Herbert Patterson; Kirkwood F Adams; Richard S Schofield; Bernadette S Belgado; James A Hill; Juan M Aranda; Hossein N Yarandi; Julie A Johnson Journal: Pharmacogenet Genomics Date: 2005-04 Impact factor: 2.089
Authors: H N Sabbah; H Shimoyama; T Kono; R C Gupta; V G Sharov; G Scicli; T B Levine; S Goldstein Journal: Circulation Date: 1994-06 Impact factor: 29.690
Authors: Golareh Agha; Michael M Mendelson; Cavin K Ward-Caviness; Roby Joehanes; TianXiao Huan; Rahul Gondalia; Elias Salfati; Jennifer A Brody; Giovanni Fiorito; Jan Bressler; Brian H Chen; Symen Ligthart; Simonetta Guarrera; Elena Colicino; Allan C Just; Simone Wahl; Christian Gieger; Amy R Vandiver; Toshiko Tanaka; Dena G Hernandez; Luke C Pilling; Andrew B Singleton; Carlotta Sacerdote; Vittorio Krogh; Salvatore Panico; Rosario Tumino; Yun Li; Guosheng Zhang; James D Stewart; James S Floyd; Kerri L Wiggins; Jerome I Rotter; Michael Multhaup; Kelly Bakulski; Steven Horvath; Philip S Tsao; Devin M Absher; Pantel Vokonas; Joel Hirschhorn; M Daniele Fallin; Chunyu Liu; Stefania Bandinelli; Eric Boerwinkle; Abbas Dehghan; Joel D Schwartz; Bruce M Psaty; Andrew P Feinberg; Lifang Hou; Luigi Ferrucci; Nona Sotoodehnia; Giuseppe Matullo; Annette Peters; Myriam Fornage; Themistocles L Assimes; Eric A Whitsel; Daniel Levy; Andrea A Baccarelli Journal: Circulation Date: 2019-08-19 Impact factor: 29.690
Authors: Chen Lyu; Manyan Huang; Nianjun Liu; Zhongxue Chen; Philip J Lupo; Benjamin Tycko; John S Witte; Charlotte A Hobbs; Ming Li Journal: Brief Bioinform Date: 2021-11-05 Impact factor: 13.994